BioWorld

June 9, 2009

View Archived Issues

CSL, Talecris Drop Merger Plans Under FTC Pressure

Australian biotech CSL Ltd. and Talecris Biotherapeutics Inc. decided to abandon their $3.1 billion merger agreement rather than fight the Federal Trade Commission, which filed a suit to block the deal. (BioWorld Today) Read More

Micromet Gets Boost on Good Blinatumomab Data

Read More

As Several Report Trial Results at ADA, a New Obesity Target

Read More

XOMA's Phase I Diabetes Data Suggest New Path for Therapy

Read More

Aileron Closes $40M Series D as Stapled Peptides Near Clinic

Read More

Clinic Roundup

Read More

Other News To Note

Read More